Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA) outlined 2026 priorities focused on advancing icovamenib and BMF-650. Icovamenib, a potential first-in-class covalent menin inhibitor, showed durable glycemic benefit at 52 weeks after a 12-week regimen and completed a 60-participant food-effect study with optimal exposure when dosed within 30 minutes after a meal. Chronic toxicology studies in two species were completed and >400 subjects have been dosed. BMF-650, an oral next-generation GLP-1 receptor agonist, will report 28-day weight-loss data from Phase I in Q2 2026. Company expects Phase II enrollments in Q1 2026 and HbA1c readouts in Q4 2026.

Positive

• Phase II enrollments for icovamenib expected in Q1 2026
• HbA1c primary endpoint readouts planned for Q4 2026
• 52-week data showed sustained glycemic improvement after 12-week dosing
• Icovamenib food-effect study (60 participants) supported consistent exposure
• Completed chronic toxicology in two species and >400 subjects dosed

Negative

• Primary efficacy readouts not expected until Q4 2026
• BMF-650 weight-loss evidence limited to a 28-day Phase I study in healthy volunteers

News Market Reaction – BMEA

+2.82%

8 alerts

+2.82% News Effect

+4.0% Peak in 10 min

+$3M Valuation Impact

$110M Market Cap

0.8x Rel. Volume

On the day this news was published, BMEA gained 2.82%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $110M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Food-effect study size: 60 participants Follow-up duration: 52-week data Treatment duration: 12-week regimen +5 more

8 metrics

Food-effect study size 60 participants COVALENT-121 food-effect study for icovamenib in Q4 2025

Follow-up duration 52-week data Long-term icovamenib outcomes after finite 12-week dosing

Treatment duration 12-week regimen Finite icovamenib dosing period before 52-week follow-up

Dosing window 30 minutes Icovamenib administration within 30 minutes after a meal

Subjects treated More than 400 subjects Total number dosed with icovamenib to date

BMF-650 data window 28-day weight loss data Initial clinical data expected from Phase I BMF-650 study

Primary endpoint duration 26-week primary endpoint HbA1c reduction for COVALENT-211 and COVALENT-212

Planned enrollment Approximately 60 patients Per Phase II icovamenib study COVALENT-211 and COVALENT-212

Market Reality Check

Price: $1.37 Vol: Volume 1,452,760 is about...

normal vol

$1.37 Last Close

Volume Volume 1,452,760 is about 1.44x the 20-day average of 1,007,742, indicating elevated interest ahead of the update. normal

Technical Shares at $1.42 are trading below the 200-day MA of $1.72, despite the positive clinical and pipeline milestones outlined.

Peers on Argus

Two biotech peers in the same industry scanner (EQ and ZNTL) showed notable upsi...

2 Up

Two biotech peers in the same industry scanner (EQ and ZNTL) showed notable upside moves, but BMEA’s own direction was not captured, and no same‑day peer news was reported. Current activity appears more company-specific than a broad sector rotation.

Historical Context

5 past events · Latest: Dec 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Conference presentation	Neutral	-1.5%	Announced upcoming JPM Healthcare Conference presentation and one-on-one meetings.
Dec 9	KOL/clinical update	Positive	-0.7%	KOL interview and WCIRDC 2025 presentation on menin and icovamenib data.
Dec 5	Clinical data presentation	Positive	+3.9%	Presented COVALENT-111 results showing durable glycemic benefits and tolerability.
Dec 1	Clinical data preview	Positive	-7.3%	Announced upcoming oral presentation of 52-week icovamenib follow-up data at WCIRDC.
Dec 1	Inducement grant	Neutral	-7.3%	Reported Nasdaq Rule 5635(c)(4) inducement stock option grant to a new employee.

Pattern Detected

Recent news, often positive scientific or event updates, has frequently met with negative or muted price reactions, with only one of the last five releases seeing a clearly positive move.

Recent Company History

Over the past few months, Biomea Fusion has focused on advancing icovamenib and strengthening its leadership and capital structure. In December 2025, it highlighted multiple WCIRDC presentations and long‑term COVALENT‑111 data showing durable glycemic and C‑peptide effects. Conference and KOL updates on icovamenib and GLP‑1 combinations coincided with mixed price reactions. Corporate actions included an inducement equity grant on Nov 26, 2025 and a JPM conference presentation announcement on Dec 17, 2025. Today’s 2026 execution plan builds directly on these prior clinical and investor‑relations milestones.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-05

The company has an active S-3 shelf registration dated 2025-08-05, expiring 2028-08-05. It shows 2 recorded usages via 424B5 prospectus supplements on 2025-10-06 and 2025-10-07, indicating that the shelf has been tapped for prior capital raises. The filing is not yet effective according to the context provided.

Market Pulse Summary

This announcement details Biomea’s 2026 execution plan around icovamenib and BMF-650, including comp...

Analysis

This announcement details Biomea’s 2026 execution plan around icovamenib and BMF-650, including completed food-effect and toxicology work, 52-week follow-up data, and defined Phase II and Phase I timelines involving about 60 patients per diabetes trial. Recent history shows active capital-raising and going-concern disclosures alongside insider share purchases. Investors may focus on delivery of HbA1c and weight-loss data, financing developments, and progress toward late-stage trials as key markers of execution.

Key Terms

phase ii, glp-1 receptor agonist, menin inhibitor, pharmacokinetic, +3 more

7 terms

phase ii medical

"toward late-stage clinical development in two Phase II clinical trials in patients"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

glp-1 receptor agonist medical

"an oral next-generation GLP-1 receptor agonist candidate in clinical development"

A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.

menin inhibitor medical

"a potentially first-in-class investigational covalent menin inhibitor for diabetes"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

pharmacokinetic medical

"The study demonstrated that icovamenib achieved optimal pharmacokinetic exposure"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

toxicology studies medical

"successfully completed chronic toxicology studies in two species for icovamenib"

Toxicology studies are safety tests that measure whether a drug, chemical or product can cause harm to people, animals or the environment, often using cells, animals or lab models to spot toxic effects and safe dose ranges. Investors care because these results influence regulatory approval, development costs, timelines and legal risk—much like crash tests signal whether a car is safe to sell and how much fixing or redesign it might require before hitting the market.

beta-cell medical

"promote beta-cell proliferation and improve beta-cell function, addressing"

A beta-cell is a specialized cell in the pancreas that makes and releases insulin, the hormone that tells the body’s tissues to take up sugar from the blood. For investors, beta-cells matter because many diabetes drugs, biologics, and cell therapies aim to protect, replace, or boost their function—think of them as the glucose-control “thermostat” whose repair or replacement can change patient outcomes and create commercial opportunity in healthcare markets.

hba1c medical

"26-week primary endpoint evaluating HbA1c reduction in approximately 60 patients"

A1c (HbA1c) is a blood test that measures how much sugar has stuck to red blood cells over the past two to three months, giving a single number that reflects average blood glucose control—think of it as a running average score for blood sugar. Investors watch A1c because it’s a common clinical measure used to judge whether diabetes drugs, devices or care programs work, influence regulatory approvals, treatment guidelines and market demand.

AI-generated analysis. Not financial advice.

• Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapies
• Successfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies
• Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimen
• Advancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic benefits
• Company to share 2026 strategy at the 44th Annual J.P. Morgan Healthcare Conference
  

SAN CARLOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its execution priorities for 2026. The Company enters the year with strong operational momentum and a defined plan across its investigational metabolic programs, led by icovamenib, a potentially first-in-class investigational covalent menin inhibitor for diabetes, and BMF-650, an oral next-generation GLP-1 receptor agonist candidate in clinical development for obesity and metabolic disorders. Biomea remains focused on disciplined execution of its development strategy, advancing medicines designed to modify the underlying biology of diabetes and obesity with the goal of delivering durable clinical benefits.

“We are entering 2026 with clarity, alignment, and a commitment to execution,” said Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member. “We know what needs to be done and we are focused on doing it. We believe icovamenib has the potential to redefine the treatment for insulin-deficient diabetes and those type 2 diabetes patients currently failing on GLP-1 therapies. We are also excited with our clinical progress with BMF-650 which strengthens our position in obesity care with a potentially more patient-friendly designed oral GLP-1 therapy. Our objective this year is straightforward, execute on our clinical plans and to deliver against the clinical milestones we have set out.”

Icovamenib: Advancing Toward Late-Stage Clinical Development
Icovamenib is a potentially first-in-class investigational small molecule covalent menin inhibitor that has been shown to promote beta-cell proliferation and improve beta-cell function, addressing an underlying disease driver in diabetes. The therapy continues to demonstrate meaningful and durable clinical benefits in patients with insulin deficiency, a subgroup of T2D associated with reduced beta-cell function, higher complication risk, and limited treatment options. Recently reported 52-week data further supports icovamenib’s potential to deliver sustained glycemic improvement in this subgroup following a finite 12-week dosing period, reinforcing its differentiated approach focused on beta-cell health.

Importantly, the 52-week data analysis also demonstrated clinically meaningful benefit in patients who were receiving GLP-1-based therapy at study entry but had not achieved glycemic targets, supporting the potential use of icovamenib alongside incretin-based treatment. Together with mechanistic data, showing enhancement of GLP-1 receptor and insulin expression, we believe these results continue to strengthen the rationale for advancing icovamenib as both a standalone option in severe insulin-deficient diabetes and a complementary treatment approach in patients who are not adequately controlled on GLP-1-based therapies.

During the fourth quarter of 2025, Biomea completed the COVALENT-121 food-effect study in 60 participants. The study demonstrated that icovamenib achieved optimal pharmacokinetic exposure, while demonstrating a generally favorable safety profile in line with prior clinical data when administered within 30 minutes after a meal. These data play an important role in our future clinical plans potentially ensuring consistent drug exposure and appropriate dosing as the Company prepares to dose the first patients in its Phase II studies, COVALENT-211 and COVALENT-212.

In addition, Biomea has successfully completed chronic toxicology studies in two species for icovamenib, further strengthening the program’s safety foundation. These studies demonstrated a favorable safety profile consistent with previously reported preclinical and clinical data. To date, more than 400 subjects have been dosed with icovamenib, with results indicating that the compound has been generally well-tolerated.

BMF-650: Progressing Oral GLP-1 Development
BMF-650 represents Biomea’s commitment to advancing next-generation accessible metabolic care through patient-friendly therapy options. BMF-650 is an orally administered, next-generation small molecule GLP-1 receptor agonist endowed with enhanced oral bioavailability, favorable pharmacokinetic profile, and reduced variability to support effective, patient-friendly treatment.

Biomea plans to continue clinical advancement of BMF-650 in 2026, with initial 28-day weight loss clinical data expected in the second quarter of 2026 from the Phase I study in obese otherwise healthy volunteers.

Biomea’s anticipated 2026 milestones include:

• COVALENT-211, Phase IIb, icovamenib in insulin-deficient type 2 diabetes, with first patient enrollment expected in the first quarter of 2026 and readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately 60 patients expected in the fourth quarter of 2026.
• COVALENT-212, Phase II, icovamenib in type 2 diabetes patients inadequately controlled on GLP-1-based therapies (i.e., semaglutide), with first patient enrollment expected in the first quarter of 2026 and readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately 60 patients expected in the fourth quarter of 2026.
• GLP-131, Phase I, BMF-650 in obese, otherwise healthy volunteers, with completion of single- and multiple-ascending dose cohorts and final 28-day weight-loss data expected in the second quarter of 2026.
• Continued proactive regulatory engagement and collaboration with clinical and scientific experts to support progression toward late-stage development.
• Anticipate completion of additional preclinical studies in relevant diabetes models to further evaluate the potential of icovamenib and BMF-650 across selected diabetes and obesity subpopulations.
  

Mick Hitchcock, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at biomeafusion.com. A replay of the webcast will be available following the live presentation.

About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. 

Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including icovamenib and BMF-650, the potential of icovamenib as a treatment for T2D, the potential of BMF-650 as a treatment for obesity; our research, development and regulatory plans, the timing of initiation, patient enrollment and dosing, progress and availability of data from our clinical trials; the mechanism of action of our product candidates and development programs; our engagement with regulatory authorities and collaboration with clinical and scientific experts; and the results and timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays or adverse outcomes in regulatory interactions, preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea Fusion’s business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com

FAQ

What are Biomea Fusion's enrollment timelines for the BMEA COVALENT-211 and COVALENT-212 trials?

Both COVALENT-211 and COVALENT-212 are expected to begin first patient enrollment in Q1 2026.

When will Biomea report the primary HbA1c readouts for icovamenib (BMEA)?

The 26-week primary endpoint HbA1c readouts for both Phase II studies are planned for Q4 2026.

What clinical data supports icovamenib's potential as a diabetes treatment (BMEA)?

Reported 52-week data showed sustained glycemic improvement after a finite 12-week dosing period and mechanistic signals supporting beta-cell effects.

When will Biomea release BMF-650 28-day weight-loss data for BMEA?

Final 28-day weight-loss data from the Phase I obese volunteer study are expected in Q2 2026.

What safety and exposure data exist for icovamenib (BMEA)?

A 60-participant food-effect study showed optimal pharmacokinetic exposure when dosed within 30 minutes after a meal, and chronic toxicology in two species was completed.

How can investors watch Biomea's J.P. Morgan presentation on January 14, 2026 (BMEA)?

The company will webcast the presentation live on January 14, 2026; a replay will be available afterward on the investor website.